The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A retrospective analysis of the prevalence of EGFR or KRAS mutations in patients (pts) with crizotinib-naïve and crizotinib-resistant, ALK-positive non-small cell lung cancer (NSCLC).
Justin F. Gainor
No relevant relationships to disclose
Anna M. Varghese
Honoraria - Illumina (I)
Sai-Hong Ignatius Ou
No relevant relationships to disclose
Sheheryar Kabraji
No relevant relationships to disclose
Mark M Awad
No relevant relationships to disclose
Ryohei Katayama
No relevant relationships to disclose
Amanda Pawlak
No relevant relationships to disclose
Mari Mino-Kenudson
No relevant relationships to disclose
Beow Y. Yeap
No relevant relationships to disclose
Gregory J. Riely
Consultant or Advisory Role - ARIAD; Celgene; Chugai Pharma; Daiichi Sankyo; Foundation Medicine; Novartis; Tragara Pharmaceuticals
Research Funding - Bristol-Myers Squibb; Chugai Pharma; Concordia Pharmaceuticals; GlaxoSmithKline; Infinity; Merck; Millennium; Novartis; Pfizer
Anthony John Iafrate
Consultant or Advisory Role - Bio-Reference Laboratories
Maria E. Arcila
No relevant relationships to disclose
Marc Ladanyi
No relevant relationships to disclose
Jeffrey A. Engelman
Stock Ownership - GATEKEEPER Pharmaceuticals
Research Funding - AstraZeneca; Novartis; Sanofi
Dora Dias-Santagata
Consultant or Advisory Role - Bio-Reference Laboratories
Alice Tsang Shaw
Consultant or Advisory Role - ARIAD; Chugai Pharma; Daiichi Sankyo; Novartis; Pfizer